Brain Metastases in Norway - A Prospective Cohort Study

Launched by OSLO UNIVERSITY HOSPITAL · Nov 14, 2017

Keywords

ClinConnect Summary

This clinical trial, called "Brain Metastases in Norway," is studying how brain metastases (cancer that has spread to the brain from other parts of the body) are currently treated in Norway. The researchers aim to gather information on how often brain metastases occur, the different treatments patients receive, how these treatments may vary between hospitals, and how they affect patients' quality of life. They also want to identify what factors help manage the disease and improve survival rates, as well as ways to enhance how brain metastases are staged (or classified).

To participate in this study, eligible patients must be at least 18 years old, have a confirmed diagnosis of solid tumors that have spread to the brain, and be able to provide consent in Norwegian. However, individuals with primary brain tumors or certain blood cancers, those who have previously been diagnosed or treated for brain metastases, and those unable to give consent are not eligible. Participants will be expected to follow study procedures, which may involve assessments and questionnaires to better understand their treatment experiences and health outcomes. This information will help improve treatment practices for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Verified cancer diagnosis of solid tumors (based on radiological, histological/cytological or operative evidence).
• • Brain metastases verified by computer tomography (CT), contrast-enhanced magnetic resonance imaging (MRI), or surgical biopsies
• • Age ≥ 18 years
• • Able to comply with study procedures
• • Able to provide written informed consent after information in Norwegian
• Exclusion Criteria:
• • Primary brain tumors
• • Primary hematological malignancies (lymphomas, leukemias)
• • Previous diagnosis and/or treatment of BM
• • Unable to produce written informed consent after information in Norwegian